As of Nov 25
| +3.15 / +1.09%|
The 16 analysts offering 12-month price forecasts for Biogen have a median target of 384.00, with a high estimate of 450.00 and a low estimate of 266.00. The median estimate represents a +31.37% increase from the last price of 292.30.
The current consensus among 21 polled investment analysts is to Buy stock in Biogen. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.